NDAORALTABLETPriority Review
Approved
Oct 1991
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
Priority Review
BIAXIN (clarithromycin) by AbbVie is clinical pharmacology pharmacokinetics clarithromycin is rapidly absorbed from the gastrointestinal tract after oral administration. Approved for helicobacter pylori infection, community acquired bacterial pneumonia, respiratory tract infection and 2 more indications. First approved in 1991.
Drug data last refreshed 20h ago
Mechanism of Action
CLINICAL PHARMACOLOGY Pharmacokinetics Clarithromycin is rapidly absorbed from the gastrointestinal tract after oral administration. The absolute bioavailability of 250 mg clarithromycin tablets was approximately 50%. For a single 500 mg dose of clarithromycin, food slightly delays the onset of…
Worked on BIAXIN at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.